Hedlund, Per Olov <br/><br/>
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.  [electronic resource] 

 -  Scandinavian journal of urology and nephrology  Nov 2011 
 - 346-53 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1651-2065 
<br/><br/><label>Standard No.: </label>10.3109/00365599.2011.585820  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents, Hormonal--administration & dosage<br/>Cardiovascular Diseases--complications<br/>Combined Modality Therapy<br/>Estradiol--administration & dosage<br/>Estrogens--administration & dosage<br/>Flutamide--administration & dosage<br/>Humans<br/>Infusions, Parenteral<br/>Male<br/>Neoplasm Metastasis<br/>Orchiectomy<br/>Prognosis<br/>Prostatic Neoplasms--pathology<br/>Risk Factors<br/>Triptorelin Pamoate--administration & dosage